Frontline TIL Combination Shows Long Follow Up in Melanoma

Company Iovance Biotherapeutics Event Type Phase 2 final cohort (ESMO) Modality Autologous tumor-infiltrating lymphocyte therapy plus anti-PD-1 Asset Lifileucel plus pembrolizumab Target Tumor antigens; PD-1 Disease Area Untreated advanced melanoma Summary Iovance’s final 24-patient Phase 2 cohort of lifileucel plus pembrolizumab in untreated advanced melanoma…